Helicos BioSciences (HLCS) Announces Research Collaboration with City of Hope

April 15, 2008 7:36 AM EDT

Helicos BioSciences (NASDAQ: HLCS) announced a research collaboration with City of Hope focused on cancer molecular diagnostics. City of Hope will use Helicos’ proprietary True Single Molecule Sequencing (tSMS)TM technology for the examination of known cancer-associated gene variants and the potential discovery of new mutations within those genes.

Helicos’ proprietary tSMS technology directly sequences single molecules of DNA or RNA, an advance that enables unparalleled accuracy, simplicity and scale in genomic experimentation. With the ability to analyze billions of single molecules simultaneously, tSMS technology can directly measure the large sample numbers required to assess the frequency of gene variants within a population of individuals or within a tumor.

Helicos BioSciences Corporation (Helicos) is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. [SM]

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?